Trial Information

Evaluation of the Expression of the Cancer Stem Cell Marker ALDH1 as a Predictor of Adjuvant Chemotherapy Response in Breast Cancers of High Risk Women in SWOG-9313

OBJECTIVES:

Primary

- To determine if ALDH1 positivity, as determined by IHC staining, identifies a poor
prognostic subgroup of women with early-stage breast cancer who have been uniformly
treated with adjuvant doxorubicin and cyclophosphamide on clinical trial SWOG-9313.

Secondary

- To determine associations of ALDH1 expression with other known factors that have been
determined on clinical trial SWOG-9313, such as estrogen receptor (ER) status, HER2
status, TOPOII, cyclin E, and p27.

- To determine if ALDH1 positivity, as determined by IHC staining, identifies a poor
prognostic subgroup within ER and HER2 subgroups in patients treated on clinical trial
SWOG-9313.

OUTLINE: This is a multicenter study.

Tumor tissue samples from clinical trial SWOG-9313 are analyzed for ALDH1 expression by IHC.